Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 12

Trial Status

Terminated1
Other1

Role Distribution

Other Roles2

Activity Timeline

Clinical Trials (2)

NCT05228015Phase 1Terminated
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Epithelioid Hemangioendothelioma (EHE)Malignant Pleural Mesothelioma (MPM)NF2 Deficiency+5 more
StudydirectorStart date: 2022-01-07
NCT05472506Phase 1Withdrawn
Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
Head and Neck CancerHead and Neck Squamous Cell CarcinomaHead Cancer+3 more
Studydirector

Research Network

Collaboration Network

3 collaborators·2 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Caroline Germa, MD

Ikena Oncology

Very Similar
2 trials

Shared therapeutic areas:

Advanced Solid TumorsEpithelioid Hemangioendothelioma (EHE)Malignant Pleural Mesothelioma+6 more

Worked with same sponsors:

Ikena Oncology
Collaborated on 1 trial
Similarity Score94%

Karim Malek, MD

Ikena Oncology

Very Similar
2 trials

Shared therapeutic areas:

Cancer of Head and NeckSquamous Cell Carcinoma of Head and NeckCancer of Head+4 more

Worked with same sponsors:

Bristol-Myers SquibbIkena Oncology
Collaborated on 1 trial
Similarity Score74%

yuankai shi, MD

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Related
17 trials

Shared therapeutic areas:

Squamous Cell Carcinoma of Head and NeckCancer of Head and NeckSolid Tumor
Similarity Score6%

Nancy Lee, MD

Memorial Sloan Kettering Cancer Center

Related
18 trials

Shared therapeutic areas:

Cancer of Head and NeckSquamous Cell Carcinoma of Head and NeckSolid Tumor
Similarity Score6%

You Lu, MD

West China Hospital

Related
18 trials

Shared therapeutic areas:

Advanced Solid TumorsSolid Tumor
Similarity Score4%

Barbara Murphy, MD

Vanderbilt-Ingram Cancer Center

Related
14 trials

Shared therapeutic areas:

Cancer of Head and NeckSolid Tumor
Similarity Score4%

Alice P Chen, M.D.

National Cancer Institute (NCI)

Related
18 trials

Shared therapeutic areas:

Advanced Solid TumorsSolid Tumor
Similarity Score4%

Zhenfeng Zhang, MD, PhD

Second Affiliated Hospital of Guangzhou Medical University

Related
21 trials

Shared therapeutic areas:

Cancer of Head and NeckSolid Tumor
Similarity Score4%

Aung Naing, Md

M.D. Anderson Cancer Center

Related
16 trials

Shared therapeutic areas:

Solid TumorAdvanced Solid Tumors
Similarity Score4%

lin shen

Peking University Cancer Hospital & Institute

Related
31 trials

Shared therapeutic areas:

Advanced Solid TumorsSolid Tumor
Similarity Score4%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT05228015Phase 1StudyDirector

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Epithelioid Hemangioendothelioma (EHE)Malignant Pleural Mesothelioma (MPM)NF2 Deficiency+5 more
Terminated
NCT05472506Phase 1StudyDirector

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

Head and Neck CancerHead and Neck Squamous Cell CarcinomaHead Cancer+3 more
Withdrawn

All 2 trials loaded